Patents by Inventor Charles Bosworth

Charles Bosworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158375
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 16, 2024
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Soultana KATSINA
  • Patent number: 11969212
    Abstract: Disclosed herein are methods and apparatus for making a determination about a cataract in an eye in ambient lighting conditions.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: April 30, 2024
    Assignee: Ohio State Innovation Foundation
    Inventors: Melissa Bailey, Charles Bosworth
  • Publication number: 20230399317
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: October 20, 2021
    Publication date: December 14, 2023
    Inventors: Charles BOSWORTH, Mark Richard STEWART, Hila BARASH, Nicholas Andrew CHAPMAN, Robert M. BURK, Ian HOLMES, Marc GLEESON, Yair ALSTER, Omer RAFAELI, Jonathan DUNN
  • Publication number: 20230357207
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 9, 2023
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
  • Publication number: 20230346832
    Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
    Type: Application
    Filed: December 5, 2022
    Publication date: November 2, 2023
    Inventors: Yair ALSTER, Charles BOSWORTH, Hila EPSTEIN-BARASH, Omer RAFAELI
  • Publication number: 20230348517
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 2, 2023
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN
  • Publication number: 20230210366
    Abstract: Disclosed herein are methods and apparatus for making a determination about a cataract in an eye in ambient lighting conditions.
    Type: Application
    Filed: February 28, 2023
    Publication date: July 6, 2023
    Inventors: Melissa Bailey, Charles Bosworth
  • Patent number: 11643429
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: May 9, 2023
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn
  • Patent number: 11634411
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 25, 2023
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
  • Publication number: 20230000675
    Abstract: Provided herein are devices and methods for applying a medicament to an eyelid, e.g. eyelid margin, of a patient while protecting the adjunct ocular tissues such as the cornea.
    Type: Application
    Filed: July 6, 2022
    Publication date: January 5, 2023
    Inventors: Yair ALSTER, Omer RAFAELI, Marc GLEESON, Charles BOSWORTH, Eitan SHARIFF, Dan TEBOUL
  • Publication number: 20220409657
    Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
    Type: Application
    Filed: July 8, 2022
    Publication date: December 29, 2022
    Inventors: Yair ALSTER, Charles BOSWORTH, Hila EPSTEIN-BARASH, Omer RAFAELI
  • Patent number: 11517586
    Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: December 6, 2022
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Yair Alster, Charles Bosworth, Hila Epstein-Barash, Omer Rafaeli
  • Publication number: 20220332749
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 20, 2022
    Inventors: Ian HOLMES, Yair ALSTER, Hila EPSTEIN-BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
  • Publication number: 20220332748
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 20, 2022
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
  • Publication number: 20220323487
    Abstract: Provided herein are pharmaceutical compositions and methods treating Demodex or a disorder thereof around the eye by application of a metered dose of a semi-solid product from a product tube.
    Type: Application
    Filed: May 2, 2022
    Publication date: October 13, 2022
    Inventors: Omer RAFAELI, Charles BOSWORTH, Marc GLEESON, Yair ALSTER, Hadas RAPAPORT
  • Patent number: 11459351
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 4, 2022
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Robert M. Burk, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls
  • Publication number: 20220305052
    Abstract: Provided herein are pharmaceutical compositions and methods treating a disorder or disease around the eye by application of a low-volume, metered dose of a semi-solid selenium disulfide product.
    Type: Application
    Filed: May 2, 2022
    Publication date: September 29, 2022
    Inventors: Yair ALSTER, Omer RAFAELI, Charles BOSWORTH, Hadas RAPAPORT
  • Publication number: 20220233584
    Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).
    Type: Application
    Filed: April 18, 2022
    Publication date: July 28, 2022
    Inventors: Charles BOSWORTH, Yair ALSTER, Hila EPSTEIN-BARASH, Omer RAFAELI, Marc GLEESON
  • Patent number: 11324775
    Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: May 10, 2022
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Charles Bosworth, Yair Alster, Hila Epstein-Barash, Omer Rafaeli, Marc Gleeson
  • Publication number: 20210401877
    Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Inventors: Yair ALSTER, Charles BOSWORTH, Hila EPSTEIN-BARASH, Omer RAFAELI